Cook eyes December launch for pelvic congestion syndrome diagnostic:
This article was originally published in Clinica
Executive Summary
Cook Women's Health plans to complete the CE-marking of its transcervical pelvic venogram (TPV) set for diagnosing pelvic congestion syndrome (PCS), by December 2006. The test, which is already approved in the US for performing basic hysterograms and transcervical venography, works by injecting a water-soluble, radiopaque contrast medium into the fundal myometrium at the top of the uterus. The medium is picked up by the veins and then monitored using fluoroscopic imaging. PCS is characterised by hyperdilated vasculature and poor clearance of the dye. PCS is one of the many causes of chronic pelvic pain, and affects around 15% of women aged 18-50, claims Cook.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.